KNSA Kiniksa Pharmaceuticals International, plc: institutional ownership and insider trading
291 funds reported holding $3.22B of Kiniksa Pharmaceuticals International, plc in their latest 13F filings; in Q2 2026 funds net bought $50.1M, with 67 new positions and 26 funds selling out; over the last 12 months insiders bought $0 and sold $47.8M on the open market; over its last four quarters it reported revenue of $841M and net income of $80.7M.
KNSA revenue and earnings
- Quarter ended Jun 30, 2026: revenue $244M, net income $25.4M, EPS 0.30
- Quarter ended Mar 31, 2026: revenue $214M, net income $22.6M, EPS 0.27
- Quarter ended Dec 31, 2025: revenue $202M, net income $14.2M, EPS 0.18
- Quarter ended Sep 30, 2025: revenue $181M, net income $18.4M, EPS 0.23
Famous investors holding KNSA
- Two Sigma (Two Sigma Investments): $35.9M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $36.4M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $4.35M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $5.97M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $3.93M, 0.0% of the portfolio
Largest institutional holders of KNSA
- FMR LLC — $446M
- Rubric Capital Management LP — $256M
- BAKER BROS. ADVISORS LP — $181M
- BlackRock, Inc. (BLK) — $175M
- TANG CAPITAL MANAGEMENT LLC — $145M
- VANGUARD GROUP INC — $128M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $122M
- VANGUARD CAPITAL MANAGEMENT LLC — $87.0M
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $64.7M
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP — $61.2M
Recent KNSA insider trades
- Sep 3, 2026: Megna Michael R sold 4,600 shares ($369K)
- Jul 29, 2026: Cole G Bradley sold 3,673 shares ($299K)
- May 1, 2026: Paolini John F. sold 58,424 shares ($3.14M)
- May 1, 2026: Patel Sanj K sold 48,565 shares ($2.62M)
5%+ owners
- FMR LLC: 14.8% (Schedule 13G/A, filed May 6, 2026)
- Julian C. Baker: 7.0% (Schedule 13D/A, filed May 26, 2026)
- BlackRock, Inc.: 5.5% (Schedule 13G, filed Jul 29, 2026)